Hepatocellular carcinoma (HCC) is a common cancer with high mortality. The limited therapeutic options for advanced disease include treatment with Sorafenib, a multikinase inhibitor whose targets include the Mediator kinase CDK8. Since CDK8 has reported oncogenic activity in Wnt-dependent colorectal cancer, we investigated whether it is also involved in HCC. We find that CDK8 and its paralogue CDK19 are significantly overexpressed in HCC patients, where high levels correlate with poor prognosis. Liver-specific genetic deletion of CDK8 in mice is well supported and protects against chemical carcinogenesis. Deletion of either CDK8 or CDK19 in hepatic precursors had little effect on gene expression in exponential cell growth but prevented oncogene-induced transformation. This phenotype was reversed by concomitant deletion of TP53. These data support important and non-redundant roles for mediator kinases in liver carcinogenesis, where they genetically interact with the TP53 tumor suppressor.
Introduction
The cyclin-dependent kinase CDK8 is the principal catalytic subunit of the Mediator complex kinase module (1) . In mice, genetic deletion of CDK8 or its activating subunit, cyclin C, is embryonic lethal (2, 3) . Vertebrate genomes encode a second paralogue of CDK8, CDK19, which also binds cyclin C and can replace CDK8 in the kinase module of Mediator (4, 5) . CDK8 may act as an oncogene in several tumor types, including melanoma and colorectal cancer (CRC) (6, 7) . Amplification of the CDK8 gene was found in 14% of CRC patients, and reversing CDK8 over-expression in CRC cells with amplified CDK8 reduced cell proliferation by interfering with the βcatenin pathway (6, 8) . CDK8 was also uncovered in a mouse transposon-mediated mutagenesis screen for genes whose alteration contributes to intestinal cancer (9) .
However, intestine-specific Cdk8 deletion in mice failed to confirm an oncogenic role in intestinal tumorigenesis triggered by mutation of the tumor suppressor Apc ((10), and our unpublished results).
CDK8 acts as a co-factor of many transcriptional activators and participates in regulating the expression of a large number of genes, including immediate early genes (11) (12) (13) (14) , targets of β-catenin (6) , p53 (15) , c-Myc (16) , Hypoxia-inducible factor 1a (HIF1a) (17, 18) , Nuclear-factor kappa B (NFkB) (19) and Notch1 (3, 20) . CDK8 expression appears to maintain tumors in an undifferentiated state by regulating c-Myc programmes (16) . CDK8 was also identified as a crucial regulator of tumor-promoting activity of senescent cells (21) . It is presently unclear how these multiple pathways participate in tumor promotion by CDK8, and whether its paralogue CDK19 has similar roles in tumorigenesis.
Since the oncogenic roles of CDK8 in Wnt-dependent CRC have been well documented in the context of constitutive Wnt signalling, we wondered whether it also has roles in hepatocellular carcinoma (HCC), another tumor type frequently associated with activation of Wnt/β-catenin signalling (22) . HCC is the main primary liver tumor and one of the most deadly cancers worldwide (23) . Mutations in the CTNNB1 gene, coding for β-catenin, are found in around 30% of patients and are mainly associated with the well differentiated, less aggressive, class of HCC (groups G5 -G6) (22, 24) .
CDK8 is expressed in the liver, where it may regulate lipogenesis (25) . Importantly, lipid accumulation as well as de novo lipid biosynthesis and the resulting lipotoxicity lead to hepatic inflammation, constituting major risk factors for liver tumorigenesis (22) .
In this study, we show that although CDK8 has a limited role in liver homeostasis both CDK8 and CDK19 paralogues are required for hepatic carcinogenesis in the context of wild-type p53.
Results

CDK8 and CDK19 are highly expressed in p53-mutated hepatocellular carcinoma
To test whether expression of CDK8 or that of its paralogue CDK19 is altered in hepatic carcinogenesis, we first quantified by qRT-PCR their expression in a large cohort of HCC patients (n=268, Supplemental Table 1 ). We found that both CDK8 and CDK19 are significantly overexpressed in HCC tumors compared to non-tumoral counterparts or normal liver ( Figure 1A ). Moreover, we detected a correlation between the expression of the two kinases in HCC ( Figure 1B ), as previously observed in breast cancer (26) . Analysis revealed no correlation with a specific aetiology (alcohol, viral infection, metabolic syndrome). However, there was a highly significant difference in CDK8/19 expression among the HCC subgroups defined by the classification based on clinical and molecular features (24, 27) : CDK8 or CDK19 high expressors were enriched in the aggressive G1-G3 subsets as compared to G4-G6 ( Figure 1C ).
Coherently, high CDK8 or CDK19 expression was correlated with mutant p53 status, molecular prognostic 5-gene score (28) and macroscopic vascular invasion ( Figure   1D , E and F). Finally, high level expression of CDK8 or CDK19 correlated with poor prognosis ( Figure 1G ). Thus our data are consistent with an oncogenic role for Mediator kinases in hepatocellular carcinoma.
CDK8 is dispensable for liver homeostasis
To investigate possible roles of the Mediator kinases in liver function and hepatic carcinogenesis, we focused on CDK8. We generated a genetically modified mouse with loxP sites flanking exon 2 of the Cdk8 gene ( Figure 2A ). Crossing these animals with transgenic mice expressing the Cre recombinase under the control of the Albumin promoter (Alb-Cre mice (29) ) gives rise to hepatocyte-specific deletion of the essential exon 2, and induces a frameshift that results in a stop codon at position 52, eliminating CDK8 protein in the liver (CDK8 Δhep animals) ( Figure 2B ).
In accordance with the absence of overt phenotype of ubiquitous Cdk8 deletion in adult animals (10) , the liver-specific deletion of CDK8 was compatible with normal liver development and we detected no change in liver physiology at the age of 3 months ( Figure 2C ). Importantly, the β-catenin-driven metabolic liver zonation was not affected by the CDK8 ablation, as judged by the purely centrilobular expression of glutamine synthetase ( Figure 2C ). Moreover, we detected no differences in the expression levels of several β-catenin target genes between the control and the CDK8 Δhep animals ( Figure 2C ). These results indicate that CDK8 is not required to regulate the β-catenin pathway under normal homeostasis conditions. However, in aging animals (> 6 months) CDK8 deficiency led to increased body weight and higher liver steatosis score ( Figure 2D ), confirming an involvement of CDK8 in liver lipogenesis (25) . Older CDK8 Δhep animals (12-15 months) did not show any sign of liver tumors (n= 12).
CDK8 is required for chemically induced liver carcinogenesis and hepatic cell transformation
We next used a model of hepatic carcinogenesis in CDK8 Δhep animals to investigate potential roles of CDK8 in liver cancer. In this model, a single injection of hepatotoxic agent diethylnitrosamine (DEN) to young mice gives rise to liver tumors after 6-8 months (30) . We sacrificed DEN-treated animals at 28 weeks, a relatively early time point in the kinetics of tumor formation, to allow detection of both positive and negative changes in tumor burden. As expected, 9 out 17 (53%) of the control Cdk8 F/F mice had at least one macroscopic liver tumor at sacrifice ( Figure 3A ). In contrast, only one out of eleven (9%) CDK8 Δhep animals had developed tumors by this time point. Cell death and regenerative response of the livers shortly after the DEN treatment were both indistinguishable between controls and CDK8 Δhep mice (Supplemental Figure 1 ), indicating that CDK8 ablation acted by inhibiting tumorigenesis rather than by interfering with the initial hepatoxicity of the treatment.
Taken together, these data support the hypothesis that CDK8 contributes to chemically-induced liver carcinogenesis in mice.
To investigate whether the effects of CDK8 loss on carcinogenesis were cell autonomous, we next isolated primary hepatic progenitor cells (BMEL) (31) from Cdk8 F/F embryos. Upon stable transfection of Cre, we obtained an efficient deletion of CDK8 from these cells ( Figure 3B ). CDK8 loss had no effect on BMEL cell morphology or growth characteristics under standard monolayer culture conditions ( Figure 3B ). As murine liver tumors triggered by DEN injection are often driven by mutated forms of Ras (30), we used forced expression of an oncogenic form of Ras, H-Ras G12V , to investigate effects of CDK8 loss on hepatic cell transformation. Similarly to previous results obtained with independent BMEL cell lines (32) , H-Ras G12V was sufficient to transform primary Cdk8 F/F BMEL cells, which then efficiently formed colonies in soft agar ( Figure 3C ). In contrast, CRE-mediated deletion of CDK8 abolished colony formation in this assay ( Figure 3C ), which is consistent with the protective role of CDK8 deletion in DEN-treated livers. Next, we used a model of tamoxifen-inducible Cre ERT2 activation. This confirmed the CDK8 requirement for Ras-induced transformation.
Strikingly, deletion of CDK8 in cells previously transformed by Ras G12V expression reverted their transformed phenotype ( Figure 3C ). To validate in vivo that CDK8 deletion protects hepatic progenitors from Ras-induced transformation, we injected CDK8 F/F Ras G12V or CDK8 -/-Ras G12V BMEL cells into the liver of immunodeficient mice.
While the Cdk8 F/F BMEL expressing Ras G12V gave rise to orthotopic tumors, their counterparts devoid of CDK8 did not ( Figure 3D ). We next disrupted Cdk8 by by CRISPR/Cas9-mediated gene disruption, wich confirmed both the absence of apparent phenotype in CDK8-depleted cells and the requirement for CDK8 for cell transformation ( Figure 3E ). Finally, to exclude that the requirement for CDK8 for transformation is specific for BMEL cells, we disrupted it by CRISPR/Cas9 in a human hepatoblastoma cell line, HepG2. As expected, the cells grew well in the absence of CDK8, but again did not form colonies in soft agar ( Figure   3E ). Altogether, our results indicate that CDK8 is required for H-Ras G12V -driven oncogenic transformation of hepatocytes and of hepatic progenitor cells.
CDK8 deletion impairs Ras G12V -driven transformation in a p53-dependent manner
We then investigated possible molecular mechanisms by which CDK8 removal could impair Ras G12V -driven transformation. Deletion of CDK8 did not abrogate Ras G12V -induced cell shape remodelling or ERK phosphorylation (Supplemental Figure   2A , B), indicating that the kinase is dispensable for Ras pathway activation. Second, constitutive activation of the β-catenin pathway in the BMEL cells did not rescue CDK8 deficiency (Supplemental Figure 2C ), indicating that tumor-promoting activity of CDK8 in the liver does not rely on the activation of the β-catenin pathway, which is consistent with the lack of β-catenin-related phenotype in CDK8 Δhep livers ( Figure 2 ). Third, CDK8 has been proposed as a regulator of glycolysis (33) , and we therefore tested whether CDK8 removal affects the metabolism of BMEL cells. However, analysis of glycolysis (Seahorse Glycolysis stress test) and mitochondrial respiration (Seahorse Mito stress test) did not reveal any effect of CDK8 ablation (Supplemental Figure 3 ), indicating that this regulation is not present in hepatic progenitor cells and that it does not account for the failure of CDK8-mutant cells to grow in soft agar.
Since CDK8 overexpression in patients correlates with mutant p53 status, we next considered the possibility that CDK8 acts by modulating p53 function. Although CDK8 can act as a coactivator of the p53 transcriptional program (34) , we observed that removal of CDK8 rather increases the level of p53 protein ( Figure 4A ), suggesting that CDK8 might restrain the tumor-suppressive functions of p53 in hepatic cells. In agreement with this idea, soft agar tests showed that the requirement for CDK8 in Rasinduced transformation was abrogated by p53 inactivation via CRISPR/Cas9 editing ( Figure 4B ). Furthermore, depletion of CDK8 did not prevent transformation of the p53deficient Huh7 cell line (Supplemental Figure 4 ). To extend these results to an in vivo setting, we triggered tumorigenesis via hydrodynamic gene delivery (HGD) (35) of the activated form of Ras together with CRISPR/Cas9-mediated inactivation of endogenous p53. HGD with Ras alone did not generate tumors, as previously described (36) , whereas simultaneous transfection with N-Ras G12D and CRISPR-p53 gave rise to multiple aggressive tumors within 4 weeks ( Figure 4C ). Consistent with the results of the cellular models, this combination of oncogenic stimuli was also fully efficient in CDK8 Δhep animals, whose hepatocytes are devoid of CDK8 ( Figure 4C ). Cell lines derived from CDK8 F/F or CDK8 -/-HGD-tumors were equally capable of giving rise to tumors when injected orthotopically into immunocompetent mice ( Figure 4D ). Our results suggest that CDK8 is required for initiation of tumorigenesis by counteracting p53 function.
Both CDK8 and CDK19 are required for Ras G12V -driven transformation
An interesting inference from the above results is that CDK19, whose expression is preserved in CDK8-deleted cells ( Figure 5A ), is insufficient to compensate for loss of CDK8, despite its high homology and redundant roles in Mediator. Furthermore, both CDK8 and CDK19 are overexpressed in a significant number of HCC patients. We therefore wondered whether CDK19 is also required for Ras-induced tumorigenesis. To test this, we deleted CDK19 in BMEL cells by CRISPR-Cas9 editing. The resulting mutant cells had unaltered morphology and proliferation kinetics ( Figure 5A ). Interestingly, CDK19 removal caused a significant upregulation of CDK8 protein levels, but not of mRNA levels, indicating a posttranscriptional feedback regulation of CDK8 in the absence of CDK19 ( Figure 5A ).
Similarly to CDK8 deletion, CDK19 ablation prevented the acquisition of the transformed phenotype upon ectopic expression of the oncogenic form of Ras, as judged by the lack of anchorage-independent growth ( Figure 5B ). Again, we obtained similar results upon CDK19 deletion in human HepG2 cells (Supplemental Figure 4 ).
Thus, both CDK8 and CDK19 are required for Ras-driven transformation of primary hepatic progenitors, neither paralogue being able to compensate for the absence of the other.
As CDK8 and CDK19 constitute the only members of the CDK module regulating transcriptional activity of the mediator complex, one hypothesis to account for the requirement of simultaneous presence of both kinases is that they control different subsets of target genes, both of which are needed for transformation by H-Ras G12V . To test this hypothesis, we analyzed gene expression profiles of the Rasexpressing BMEL cells in the presence or absence of CDK8 or CDK19 by RNA-seq ( Figure 5C) . Surprisingly, disruption of either CDK8 or CDK19 had only minor effects on gene expression, with only around 30 genes reproducibly showing more than 2-fold differences in expression between cells expressing Ras G12V with or without deletion of Cdk8 or Cdk19. At this threshold of fold-change, we did not identify common genes deregulated by the absence of either kinase ( Figure 5D ). However, even though neither CDK8 -/nor CDK19 -/cells can be transformed by the oncogenic form of Ras, Ras G12V caused deregulation of over 1000 genes, irrespective of the status of Cdk8 and Cdk19 when growing in exponential culture, explaining their indistinguishable morphology. This result further shows that, despite the importance of Mediator for gene regulation, neither CDK8 nor CDK19 are required for implementing wide-ranging changes to gene expression, suggesting that their effects in carcinogenesis, which involve p53, are not due to major transcriptional changes.
Discussion
Combining patient data and mouse models, we provide evidence that both Mediator kinases, CDK8 and CDK19, are involved in hepatocellular carcinoma. Our data indicate that these CDKs are required for initiation of tumorigenesis induced by mutation of a strong oncogene, Ras. To our knowledge, this is the first indication that the CDK8 paralogue CDK19 is required for cell transformation, indicating nonredundant functions for both kinases in facilitating tumorigenesis.
We find that removal of CDK8 in hepatocytes has no major consequences for liver functions, as previously indicated by the ubiquitous inactivation of the kinase in adult animals (10) . However, we observed that CDK8 depletion induces steatosis in aging animals, in accordance with a role for the kinase as repressor of lipogenesis (25) . In contrast to its mild effects on liver physiology, CDK8 disruption has a strong impact on hepatic carcinogenesis. We observed a major reduction of chemically induced tumorigenesis, and a complete protection from Ras-induced cell transformation. This requirement is further highlighted by the fact that CDK8 ablation occurring after Ras G12V -induced transformation is able to restore the non-transformed phenotype.
CDK8 thus apparently has diverse context-specific involvement in various cancers. CDK8 was initially described to have oncogenic properties in Wnt-dependent colorectal cancers, where it controls the beta-catenin pathway (6, 8) and maintains Myc functions (37) . However, this was not confirmed genetically in mouse models; indeed, if anything, CDK8 knockout marginally increased progression from early lesions to tumors (10) . A recent study also found no effect of CDK8 knockdown on growth of colorectal tumors in syngeneic mice, but it prevented liver metastases (38) .
Furthermore, CDK8 promotes proliferation of melanoma cell lines (7) and is apparently required for efficient Estrogen Receptor (ER)-dependent transcription in ER-positive breast cancer cells (39) . However, most reports of anti-tumor activity caused by interfering with CDK8 function have used kinase inhibitors (39-45) that target both CDK8 and CDK19. The most likely explanation for this is that CDK inhibitors are rarely very specific for one kinase subfamily (46) and some "CDK8/19 inhibitors" may inhibit other kinases required for efficient tumor development. This highlights the need for a genetic approach in vivo.
Other studies have suggested that as well as possessing oncogenic activity in some contexts, CDK8 may rather have tumor-suppressive activity in others, including endometrial cancers (47) , intestinal cancer (10) and T-cell acute lymphoblastic leukemia (3).
One way of reconciling these apparently different roles for Mediator kinases is to invoke possible tissue-specificity of action. We found that CDK8 deletion has no effect on hepatic cell growth, contrary to certain melanoma or gastric cancer cell lines, in which decrease of proliferation has been described (7, 48) . Tissue specificity is further demonstrated by the fact that while knockout of either kinase is well tolerated by hepatic precursor cells, germline-deletion of the Cdk8 gene in mice is lethal at preimplantation embryogenic stages (2) . Our results suggest that oncogenic activities of CDK8 and CDK19 in HCC are independent of the b-catenin pathway, and therefore likely operate through different mechanisms in colorectal and hepatic carcinogenesis.
One key finding of our study is that both CDK8 and CDK19 are required for cell transformation by H-Ras G12V . This is not due to downregulation of one kinase when the other one is removed, as, on the contrary, we found that CDK19 depletion stabilizes CDK8 protein, identifying a post transcriptional regulation of CDK8 levels. Of note, this cross-regulation is not bidirectional, as removal of CDK8 does not seem to stabilize CDK19 protein. A possible explanation for these results might be that CDK8 and CDK19 regulate transcription of specific gene sets that are both required for hepatic cell transformation. The results of our RNA-seq analysis renders this hypothesis unlikely, as very few genes are differentially transcribed in either knockout. However, we cannot exclude this entirely, as 12 genes were differentially regulated in knockouts of both Cdk8 and Cdk19 when the threshold for fold-change is removed: Adora1, Nt5e, Fgfbp1, Spp1, Gm5781, Lgals4, Rpl10-ps3, Akap12, Gm8349, Anxa10, Scd1, Ly6a.
Yet the magnitude of the gene expression change is likely too low to be biologically meaningful; the regulation of several, including Anxa10 (encoding Annexin 10A), Akap12 (encoding A Kinase Anchoring Protein-12) and Nt5e (encoding 5' nucleotidase) is in opposite directions in each knockout; and no clear roles in cancer for any of these genes have been reported. A possibility that we cannot exclude at this stage is that both CDK8 and CDK19 are required for transcription or repression of genes whose expression is only activated upon growth in foci. However, the minimal effects of deletion of either gene in shaping the transcriptome induced by expression of oncogenic Ras suggests that neither kinase is required to implement large-scale changes to gene expression, and that non-transcriptome effects should be considered.
We suggest an alternative model, which is compatible with both apparent oncogenic activity of Mediator kinases in some circumstances and lack of effects in others. In this model, CDK8/19 are not in themselves oncogenes and therefore their overexpression does not transform cells, but rather provides a favorable terrain enabling the initiation of tumorigenesis by additional oncogenic factors, including bona fide oncogenes. For example, it is well established that, rather than transforming cells directly, expression of strong oncogenes such as Ras G12V promotes premature cell senescence with accumulation of p53 and p16 (49) . BMEL cells are immortal, but have a functional wild-type p53 (50) . In this context CDK8/19 expression may attenuate the function of p53, thus unleashing the oncogenic potential of mutant Ras. We speculate that loss of p53 by mutation "fixes" the initial advantage conferred by overexpression of CDK8/19. This agrees both with our finding that in the liver, CDK8/19 are only required for cell transformation in the presence, but not the absence, of p53, and with the genetic interaction between CDK8/19 and TP53 in patients. If such a scenario was indeed true, it would suggest a therapeutic niche for CDK8/19 kinase inhibitors in cancer: they would be expected to trigger differentiation or death of tumor cells that
have not yet acquired p53 mutations. Our results warrant further investigation of CDK8/19 inhibitors as therapeutic agents for p53-positive hepatocellular carcinoma.
Material and Methods
Patients
A total of 268 fresh-frozen tissue samples of HCC, associated with various etiologies, were included in this study. Patients and tumor features were already described in previously published studies and summarized in Supplemental Table 1 . Written informed consent was obtained from all subjects in accordance with French legislation.
CDK18 and CDK19 mRNA expression levels were assessed by quantitative RT-PCR using Fluidigm 96.96 Dynamic Arrays and specific TaqMan predesigned assays (CDK8= Hs00176209_m1; CDK19= Hs00292369_m1; Life Technologies, Carlsbad, CA). Data were calibrated with the RNA ribosomal 18S and changes in mRNA expression levels were determined using a comparative CT method using 5 normal tissue samples as control. 
Mice experiments
Protein isolation and Western blotting
RNA isolation, qPCR and RNA-Seq analysis
The RNA was extracted from either cells or liver tissue and purified using RNeasy mini kit to perform a quality control of the sequencing, FastQC over the fastq files containing the raw reads. All the reads that passed the quality control were aligned to the mouse reference genome (GRCm38.p6) and the counts per gene were quantified using the tool STAR 2.6.0a (2) .
The Ensembl mouse genome annotations (release 93) were used for establishing the coordinates of each gene and their corresponding transcripts. Differential gene expression analysis was performed in R using the DESeq2 library. After normalization of the read counts per gene, a negative binomial generalized linear model was fitted considering single factor design for assessing the differential expression between CDK8/CDK19 knock-out BMEL Ras G12V transformed cells and BMEL Ras G12V transformed cells (as the control group). Wald test are performed for assessing statistical significance on the differential expression of each gene, then test are independently filtered and corrected by multiple hypothesis testing (Benjamini-Hochberg).
Statistical Analysis
Data sets were tested with 2-tailed unpaired Student t tests or Mann-Whitney U tests, correlations were analyzed with Pearson's χ 2 test using Prism Software version 8 (GraphPad).
Significant P values are shown as: *P <0.05, **P <0.01, ***P <0.001, and ****P <0.0001. CDK19 expression levels on the total number of analyzed samples was used to determine the low-and high-expression groups. P-value < 0.05 was considered as significant.
Data availability
The RNA-sequencing data have been deposited in the Gene Expression Omnibus (GEO, NCBI) repository. independent experiments (mean ± SD) are shown. * indicates an aspecific band sometimes detected with CDK8 antibody. For each experiment, the band intensity value or cDNA content of the crispr-Ctl sample was normalized to 1. P-value from one-sample t test is indicated. (B) Soft agar test for indicated BMEL cell lines. A representative well for each cell line is shown. Mean number of colonies per well ± SD from at least three independent experiments are indicated. (C) Heatmap for the RNASeq experiments. The raw counts were transform using the regularized log and the variance was calculated between all the samples for all the genes. We selected the 100 genes with the higher variance. Distance between genes and samples were computed using the euclidean measure and the hierarchical cluster analysis was perform in order to set the distance trees. Two level of colors were set to describe the sample genotypes for RAS transformation (Violet: wild type; Blue: RAS G12V mutation) and for Cdk8 or Cdk19 knock-outs (Gray: Control; Green: Cdk8 KO; Orange: Cdk19 KO). (D) Volcano plots for the differential gene expression. The values of the minus logarithm in base ten versus the logarithm in base two of the counts are plotted for each gene and two levels of significance are showed in red (genes with adjusted p-value less than 0.05) and in purple (genes with adjusted p-value less than 0.05 and with absolute values of the log2 of the fold change greater than one).
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